- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Products (Recombinant protein) | Swiss Prot# | Size | Price (US$) | Order |
PL0780 | Recombinant protein-Toxoplasma gondii Major surface antigen p30 (a.a.11 to 259) | Q7KNK3 | 100 µg | 1195 | |
PL0781 | Recombinant protein-Toxoplasma gondii Surface antigen P22 (a.a.17 to 170) | D1MJ46 | 100 µg | 1195 | |
PL0782 | Recombinant protein-Toxoplasma gondii Surface antigen (a.a.31 to 357) | A4GW64 | 100 µg | 1195 | |
PL0783 | Recombinant protein-Toxoplasma gondii SAG1-related sequence 6 (a.a.41 to 393) | Q9NH12 | 100 µg | 1195 | |
PL0784 | Recombinant protein-Toxoplasma gondii Dense granule protein 5-GRA 5-p21 (a.a.22 to 120) | Q07828 | 100 µg | 1195 | |
PL0785 | Recombinant protein-Toxoplasma gondii SAG1-related sequence 2 (a.a.31 to 372) | O15695 | 100 µg | 1195 | |
PL0786 | Recombinant protein-Toxoplasma gondii SAG5A (Surface antigen 5A) (a.a.19 to 362) | O15703 | 100 µg | 1195 | |
PL0787 | Recombinant protein-Toxoplasma gondii SAG5C (Surface antigen 5C) (a.a.31 to 367) | Q6WAW5 | 100 µg | 1195 | |
PL0788 | Recombinant protein-Toxoplasma gondii MIC3 microneme protein (a.a.22 to 359) | Q9GRG4 | 100 µg | 1195 | |
PL0789 | Recombinant protein-Toxoplasma gondii SAG1-related sequence 3 (a.a.36 to 345) | O15694 | 100 µg | 1195 | |
PL0790 | Recombinant protein-Toxoplasma gondii Fructose-bisphosphate aldolase (a.a.31 to 363) | Q8I8I2 | 100 µg | 1195 | |
PL0791 | Recombinant protein-Toxoplasma gondii Bradyzoite surface protein (a.a.28 to 172) | P90612 | 100 µg | 1195 | |
PL0792 | Recombinant protein-Toxoplasma gondii Bradyzoite surface antigen BSR4 (a.a.32 to 385) | Q95NL6 | 100 µg | 1195 | |
PL0793 | Recombinant protein-Toxoplasma gondii Surface antigen 5D (a.a.32 to 362) | Q6Y287 | 100 µg | 1195 | |
PL0794 | Recombinant protein-Toxoplasma gondii GPI-anchored surface antigen SRS4 (a.a.27 to 396) | O76660 | 100 µg | 1195 | |
PL0795 | Recombinant protein-Toxoplasma gondii Surface antigen protein 1 (a.a.18 to 173) | Q4FEC1 | 100 µg | 1195 | |
PL0796 | Recombinant protein-Toxoplasma gondii GT1 Surface protein rhoptry (a.a.52 to 456) | B9PJI9 | 100 µg | 1195 | |
PL0797 | Recombinant protein-Toxoplasma gondii GT1 Surface protein (a.a.22 to 174) | B9PWF2 | 100 µg | 1195 | |
PL0798 | Recombinant protein-Toxoplasma gondii GT1 Merozoite surface protein (a.a.31 to 406) | B9PIG7 | 100 µg | 1195 | |
PL0799 | Recombinant protein-Toxoplasma gondii ME49 SRS8 surface antigen (a.a.31 to 398) | B6KUW4 | 100 µg | 1195 | |
PL0800 | Recombinant protein-Toxoplasma gondii ME49 GPI-anchored surface antigen (a.a.40 to 391) | B6KE76 | 100 µg | 1195 | |
PL0801 | Recombinant protein-Toxoplasma gondii ME49 p18 surface antigen (a.a.29 to 180) | B6KUC9 | 100 µg | 1195 | |
PL0802 | Recombinant protein-Toxoplasma gondii ME49 Surface antigen (a.a.25 to 163) | B6K9I9 | 100 µg | 1195 | |
PL0803 | Recombinant protein-Toxoplasma gondii ME49 Bradyzoite-specific surface protein (a.a.32 to 398) | B6KPL4 | 100 µg | 1195 | |
PL0804 | Recombinant protein-Toxoplasma gondii ME49 Enolase (a.a.31 to 475) | B6KCK5 | 100 µg | 1195 | |
PL0805 | Recombinant protein-Toxoplasma gondii ME49 SRS domain-containing surface antigen (a.a.15 to 317) | B6K9J4 | 100 µg | 1195 | |
PL0806 | Recombinant protein-Toxoplasma gondii ME49 SAG2 related antigen SAG2B (a.a.17 to 190) | B6KP82 | 100 µg | 1195 | |
PL0807 | Recombinant protein-Toxoplasma gondii ME49 Surface antigen P22 (a.a.20 to 147) | B6KD48 | 100 µg | 1195 | |
PL0808 | Recombinant protein-Toxoplasma gondii ME49 Surface antigen 5(a.a.21 to 125) | B6KDG6 | 100 µg | 1195 | |
PL0809 | Recombinant protein-Toxoplasma gondii ME49 GPI-anchored surface protein (a.a.29 to 420) | B6KK31 | 100 µg | 1195 | |
PL0810 | Recombinant protein-Toxoplasma gondii RH GPI-anchored surface bsr4-related antigen (a.a.35 to 374) | Q1JSB4 | 100 µg | 1195 | |
RPL0780 | cDNA-Toxoplasma gondii Major surface antigen p30 (a.a.11 to 259) | Q7KNK3 | 2 µg | 1488 | |
RPL0781 | cDNA-Toxoplasma gondii Surface antigen P22 (a.a.17 to 170) | D1MJ46 | 2 µg | 918 | |
RPL0782 | cDNA-Toxoplasma gondii Surface antigen (a.a.31 to 357) | A4GW64 | 2 µg | 1956 | |
RPL0783 | cDNA-Toxoplasma gondii SAG1-related sequence 6 (a.a.41 to 393) | Q9NH12 | 2 µg | 2112 | |
RPL0784 | cDNA-Toxoplasma gondii Dense granule protein 5-GRA 5-p21 (a.a.22 to 120) | Q07828 | 2 µg | 800 | |
RPL0785 | cDNA-Toxoplasma gondii SAG1-related sequence 2 (a.a.31 to 372) | O15695 | 2 µg | 2046 | |
RPL0786 | cDNA-Toxoplasma gondii SAG5A (Surface antigen 5A (a.a.19 to 362) | O15703 | 2 µg | 2058 | |
RPL0787 | cDNA-Toxoplasma gondii SAG5C (Surface antigen 5C (a.a.31 to 367) | Q6WAW5 | 2 µg | 2016 | |
RPL0788 | cDNA-Toxoplasma gondii MIC3 microneme protein (a.a.22 to 359) | Q9GRG4 | 2 µg | 2022 | |
RPL0789 | cDNA-Toxoplasma gondii SAG1-related sequence 3 (a.a.36 to 345) | O15694 | 2 µg | 1854 | |
RPL0790 | cDNA-Toxoplasma gondii Fructose-bisphosphate aldolase (a.a.31 to 363) | Q8I8I2 | 2 µg | 1992 | |
RPL0791 | cDNA-Toxoplasma gondii Bradyzoite surface protein (a.a.28 to 172) | P90612 | 2 µg | 864 | |
RPL0792 | cDNA-Toxoplasma gondii Bradyzoite surface antigen BSR4 (a.a.32 to 385) | Q95NL6 | 2 µg | 2118 | |
RPL0793 | cDNA-Toxoplasma gondii Surface antigen 5D (a.a.32 to 362) | Q6Y287 | 2 µg | 1980 | |
RPL0794 | cDNA-Toxoplasma gondii GPI-anchored surface antigen SRS4 (a.a.27 to 396) | O76660 | 2 µg | 2214 | |
RPL0795 | cDNA-Toxoplasma gondii Surface antigen protein 1 (a.a.18 to 173) | Q4FEC1 | 2 µg | 930 | |
RPL0796 | cDNA-Toxoplasma gondii GT1 Surface protein rhoptry (a.a.52 to 456) | B9PJI9 | 2 µg | 2424 | |
RPL0797 | cDNA-Toxoplasma gondii GT1 Surface protein (a.a.22 to 174) | B9PWF2 | 2 µg | 912 | |
RPL0798 | cDNA-Toxoplasma gondii GT1 Merozoite surface protein (a.a.31 to 406) | B9PIG7 | 2 µg | 2250 | |
RPL0799 | cDNA-Toxoplasma gondii ME49 SRS8 surface antigen (a.a.31 to 398) | B6KUW4 | 2 µg | 2202 | |
RPL0800 | cDNA-Toxoplasma gondii ME49 GPI-anchored surface antigen (a.a.40 to 391) | B6KE76 | 2 µg | 2106 | |
RPL0801 | cDNA-Toxoplasma gondii ME49 p18 surface antigen (a.a.29 to 180) | B6KUC9 | 2 µg | 906 | |
RPL0802 | cDNA-Toxoplasma gondii ME49 Surface antigen (a.a.25 to 163) | B6K9I9 | 2 µg | 828 | |
RPL0803 | cDNA-Toxoplasma gondii ME49 Bradyzoite-specific surface protein (a.a.32 to 398) | B6KPL4 | 2 µg | 2196 | |
RPL0804 | cDNA-Toxoplasma gondii ME49 Enolase (a.a.31 to 475) | B6KCK5 | 2 µg | 2664 | |
RPL0805 | cDNA-Toxoplasma gondii ME49 SRS domain-containing surface antigen (a.a.15 to 317) | B6K9J4 | 2 µg | 1812 | |
RPL0806 | cDNA-Toxoplasma gondii ME49 SAG2 related antigen SAG2B (a.a.17 to 190) | B6KP82 | 2 µg | 1038 | |
RPL0807 | cDNA-Toxoplasma gondii ME49 Surface antigen P22 (a.a.20 to 147) | B6KD48 | 2 µg | 762 | |
RPL0808 | cDNA-Toxoplasma gondii ME49 Surface antigen 5(a.a.21 to 125) | B6KDG6 | 2 µg | 800 | |
RPL0809 | cDNA-Toxoplasma gondii ME49 GPI-anchored surface protein (a.a.29 to 420) | B6KK31 | 2 µg | 2346 | |
RPL0810 | cDNA-Toxoplasma gondii RH GPI-anchored surface bsr4-related antigen (a.a.35 to 374) | Q1JSB4 | 2 µg | 2034 |
Toxoplasma gondii cDNA and recombinant antigen
Toxoplasma gondii is a ubiquitous protozoan parasite that can infect a wide range of animals, including humans. This parasite has a complex life cycle that involves both sexual and asexual reproduction, and it produces various surface antigens and proteins that are essential for its survival and pathogenesis. Some of the major surface antigens and proteins produced by Toxoplasma gondii include p30, P22, SAG1-related sequence (6 and 3, 2), 5-GRA 5-p21, SAG5A, SAG5C, MIC3 microneme protein, bisphosphate aldolase, Bradyzoite surface antigen BSR4, Surface antigen 5D, SRS4, GT1, ME49 (SRS8 and GPI, p18, p22, SAG2), and RH GPI.
Toxoplasma gondii produces a variety of surface antigens and proteins that are essential for its survival and pathogenesis. These antigens and proteins include:
p30: a surface antigen that is involved in parasite invasion of host cells.
P22: a surface antigen that is involved in the attachment of the parasite to host cells.
SAG1-related sequence (SRS): a family of surface antigens that are involved in host cell invasion and immune evasion. The SRS family includes SRS6, SRS3, and SRS2.
GRA5-p21: a protein that is involved in the formation of the parasitophorous vacuole, a membrane-bound compartment where the parasite resides inside host cells.
SAG5A and SAG5C: surface antigens that are involved in host cell invasion.
MIC3: a microneme protein that is involved in host cell invasion.
Bisphosphate aldolase: an enzyme that is involved in glycolysis, a metabolic pathway that provides energy for the parasite.
Bradyzoite surface antigen BSR4: a surface antigen that is expressed by the parasite during its dormant stage (bradyzoite).
Surface antigen 5D: a surface antigen that is involved in host cell invasion.
SRS4: a surface antigen that is involved in host cell invasion.
GT1 and ME49: strains of Toxoplasma gondii that produce a variety of surface antigens and proteins, including SRS8 and GPI, p18, p22, SAG2, and RH GPI.
Toxoplasma gondii cDNA and recombinant antigens are used in a variety of applications, including diagnostic assays, vaccine development, and research. They can be used to identify T. gondii infections, detect antibodies to the organism, and develop new vaccines or therapies. The cDNA can also be used to study gene expression, analyze protein-protein interactions, and understand the molecular basis of parasite-host interactions. Additionally, the antigens can be used to detect T. gondii-specific antibodies in serum samples and to measure the effectiveness of vaccines.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple
